Before starting the treatment with BATs, AML engraftment in mice was monitored by staining for human CD45+/CD33+/CD123+/CD34+/CD38+ cells in the flushed BM on days 7, 14, and 21 (Figures 6, S4). This evidence concerns the gene CD38 and acute myeloid leukemia.